Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma.

[1]  J. Manson,et al.  A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[2]  R. Schiff,et al.  Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.

[3]  Gloria S. Huang,et al.  Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. , 2007, Gynecologic oncology.

[4]  R. Santen,et al.  Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. , 2007, Endocrinology.

[5]  B. Gunawan,et al.  Characterization of a newly established uterine carcinosarcoma cell line featuring the sarcomatous phenotype of the tumor in vitro , 2007, International Journal of Gynecologic Cancer.

[6]  A. Gown,et al.  Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. , 2007, Gynecologic oncology.

[7]  R. Broaddus,et al.  Overexpression of the Insulin-Like Growth Factor I Receptor and Activation of the AKT Pathway in Hyperplastic Endometrium , 2006, Clinical Cancer Research.

[8]  Y. Shang.  Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis , 2006, Nature Reviews Cancer.

[9]  A. Jazaeri,et al.  Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors. , 2006, American journal of obstetrics and gynecology.

[10]  C. Livasy,et al.  EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. , 2006, Gynecologic oncology.

[11]  P. Neven,et al.  Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. , 2005, Gynecologic oncology.

[12]  Joan G. Jones,et al.  Malignant Mixed Müllerian Tumor of the Uterus in a Patient Taking Raloxifene , 2005, Obstetrics and gynecology.

[13]  Margaret Warner,et al.  Reflections on the Discovery and Significance of Estrogen Receptor (cid:1) , 2005 .

[14]  A. Swerdlow,et al.  Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. , 2005, Journal of the National Cancer Institute.

[15]  I. Vergote,et al.  ERBB-2 gene overexpression and amplification in uterine sarcomas. , 2004, Gynecologic oncology.

[16]  C. Marth,et al.  Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer. , 2004, Gynecologic oncology.

[17]  I. Cohen.  Endometrial pathologies associated with postmenopausal tamoxifen treatment. , 2004, Gynecologic oncology.

[18]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[19]  M. Zafrakas,et al.  Expression of estrogen receptors alpha and beta in two uterine mesenchymal tumors after prolonged tamoxifen therapy. Report of two cases. , 2004, European Journal of Gynaecological Oncology.

[20]  I. Bièche,et al.  Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  W. McCluggage,et al.  Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas , 2002, International Journal of Gynecologic Cancer.

[22]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[23]  M. S. Dalton,et al.  Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression , 2001, Oncogene.

[24]  K. Shimizu,et al.  Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case. , 2001, Gynecologic oncology.

[25]  G. Pelletier,et al.  Immunocytochemical Localization of Estrogen Receptors α and β in the Human Reproductive Organs , 2000 .

[26]  F. Penault-Llorca,et al.  Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. , 2000, Gynecologic oncology.

[27]  J. H. Price,et al.  Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[28]  G. Pelletier,et al.  Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs. , 2000, The Journal of clinical endocrinology and metabolism.

[29]  E. Miyagi,et al.  Uterine carcinosarcoma is derived from a single stem cell: An in vitro study , 1997, International journal of cancer.

[30]  M. Evans,et al.  Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus? , 1995, International Journal of Gynecologic Cancer.

[31]  J. Orenstein,et al.  Carcinosarcoma (malignant mixed müllerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. , 1993, Human pathology.

[32]  F. Askin,et al.  Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. , 1990, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[33]  F. Vellios,et al.  Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. , 1963, American journal of clinical pathology.